(S)-N-((S)-1-cyclohexyl-2-{(S)-2-[5-(4-fluoro-phenoxy)-pyridin-3-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide | 1005342-49-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[5-(4-fluoro-phenoxy)-pyridin-3-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide
• 英文别名: (2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[5-(4-fluorophenoxy)pyridin-3-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide
• CAS: 1005342-49-3
• 化学式: C₂₇H₃₅FN₄O₃
• 分子量: 482.598
• InChiKey: CLEDYXXBPZCGOA-WDNCENIBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Organic Compounds
  申请人：CHEN Zhuoliang

  公开号：US20110065726A1

  公开（公告）日：2011-03-17

  The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.

  本发明涉及一种化合物，其化学式为：或其药用可接受的盐，并且利用这些化合物来治疗哺乳动物中的增殖性疾病，如癌症。
• COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS
  申请人：Griffin James Douglas

  公开号：US20100056467A1

  公开（公告）日：2010-03-04

  The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML.

  本发明涉及治疗血液系统恶性肿瘤的方法，包括急性髓系白血病（AML），其中包括抑制Smac蛋白与IAP结合的化合物（“IAP抑制剂”）与一种或多种药物活性剂的组合；包含该组合的药物组合物；以及包含该组合的商业包装。本发明还涉及使用IAP抑制剂与一种或多种药物活性剂的组合制备药物来治疗血液系统恶性肿瘤，包括AML。
• SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS
  申请人：Chen Zhuoliang

  公开号：US20140004101A1

  公开（公告）日：2014-01-02

  The present invention is directed to a compound of the formula: or pharmaceutically acceptable salts thereof and use of such compounds for treating proliferative diseases such as cancer, in mammals.

  本发明涉及以下式的化合物：或其药学上可接受的盐，并且利用这种化合物治疗哺乳动物的增殖性疾病，例如癌症。
• Organic compounds
  申请人：Novartis AG

  公开号：EP2537846A1

  公开（公告）日：2012-12-26

  The present invention is directed to compounds of the following formulae, which are intermediates in the synthesis of Smac peptidomimetics useful as IAP inhibitors: and

  本发明涉及以下式子的化合物，它们是合成可用作 IAP 抑制剂的 Smac 拟肽物的中间体： 和
• Immunomodulation by IAP Inhibitors
  申请人：Novartis AG

  公开号：EP2698158A1

  公开（公告）日：2014-02-19

  The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.

  本发明涉及含有 IAP 抑制剂的免疫佐剂，包括 Smac 模仿剂。 本发明进一步提供了含有 IAP 抑制剂和抗原的药物组合物和疫苗。 本发明还提供了通过施用 IAP 抑制剂增强免疫反应的方法、治疗或预防癌症的方法、治疗或预防感染的方法、治疗自身免疫性疾病的方法以及增强细胞因子或抗体产生的方法。